Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Signs on MultiPlan for Coverage of Breast Cancer Test

NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement under which healthcare providers that participate in the network of managed healthcare plan MultiPlan will offer access to GTG's BrevaGen breast cancer test.

The deal, executed by GTG's wholly owned subsidiary Phenogen Sciences, provides the company access to MultiPlan's network of 4,800 hospitals, 99,000 ancillary facilities, and 700,000 healthcare professionals across the US. MultiPlan is headquartered in Valencia, Calif., and covers approximately 39 million lives, GTG noted.

The agreement is the sixth reached between Melbourne, Australia-based GTG and a US preferred provider organization. In total, 62 million covered lives in the US now have access to the company's BrevaGen test as an in-network service, the firm said. Earlier this month, it inked a deal with the Three Rivers Provider Network.

The DNA-based BrevaGen test evaluates the presence or absence of common SNPs associated with an increased risk for developing breast cancer.

Financial and other terms of the deal were not disclosed.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.